Guardant Health Secures $600 Million in New Funding to Accelerate Transformational Precision Medicine

Guardant Health is excited to announce a remarkable milestone in its journey of transforming patient care and advancing precision medicine.

The company has successfully raised $600 million in new funding, a significant boost that will propel its mission of guarding wellness and giving individuals more time free from cancer.

Since its founding in 2012, Guardant Health has been at the forefront of revolutionizing cancer diagnostics and treatment.

Utilizing cutting-edge blood and tissue tests, real-world data, and AI analytics, the company provides critical insights that help decipher what drives disease.

This substantial capital infusion will further accelerate the ongoing development, enhancement, and commercial expansion of its innovative testing portfolio, which includes groundbreaking solutions like Guardant360®, Guardant360® CDx, Guardant360 TissueNext®, Guardant360 Response™, and GuardantINFINITY™ for advanced-stage cancer patients, as well as Guardant Reveal® for early-stage cancer detection.

Additionally, the FDA-approved Shield™ test reinforces Guardant Health’s commitment to meeting the screening needs of individuals who are eligible for early intervention.

This investment not only underscores the confidence of investors in the robust potential of precision oncology but also provides the means to scale operations, enhance research and development efforts, and expand access to innovative diagnostic tools that are essential in the fight against cancer.

In this new chapter, Guardant Health is poised to lead further advancements in precision medicine, ensuring that more patients can benefit from early diagnosis and tailored treatment options.

With this funding, Guardant Health reaffirms its determination to stay ahead of the curve in the fight against cancer, ultimately delivering hope and enhanced outcomes to countless individuals worldwide.